In addition to upregulation in solid tumor and hematological malignancies (Poke et al., 2010), we previously found that PRMT5 is dysregulated in HTLV-1-transformed T-cells, lymphocytic leukemia T-cell lines, and ATL patient PBMCs. This evidence concerns the gene PRMT5 and hematologic disorder.